Sydney cancer immunotherapy research company, Imugene has presented positive vaccine trial results at the Annual American Association for Cancer Research.
The results were released after a trial period on a genetically identical mouse-model subject with HER-2+ breast cancer.
B-cell cancer growth was inhibited in the test subject after implementation of the newly developed mimitope programmed cell death protein (PD-1).
The PD-1 elicited an antibody response in the mouse that inhibited growth of the cancer tumor.
Imugene collaborated with the Medical University of Vienna at the Annual American during the trial tests.
Please read the announcement attached.
More From The Market Online
Market shrugs as Fisher & Paykel announces mass recall
Fisher & Paykel has initiated a voluntary limited recall of batches of Airvo 1 and my…
- Keely Lynch
- 2 mins
- 28 March 2024 14:58 (AEDT)
Brian Leedman’s BlinkLab to join ASX: AI-driven smartphone app screens for autism, ADHD
BlinkLab is a world-first, AI-driven digital healthcare venture, that uses a smartphone and facial recognition to…
- Sonia Madigan
- 4 mins
- 28 March 2024 08:54 (AEDT)
Osteopore stock spikes 900% on Singapore and Vietnam approvals
Osteopore's (ASX:OSX) share price was up 38% after the regenerative medicine company received approval for its…
- Fouad Haidar
- 2 mins
- 27 March 2024 11:43 (AEDT)
Amplia Therapeutics takes step up in pancreatic cancer treatment
Amplia Therapeutics is on to next step in its pancreatic cancer treatment research after a successful…
- Fouad Haidar
- 2 mins
- 27 March 2024 16:11 (AEDT)